US Stock Alert: ImmunityBio Plunges on November 20th Due to Double Miss in Q3 Results, Widened Net Loss, and Ongoing Going Concern Doubts
Bitget异动解读2026/11/20 17:45ImmunityBio November 20: Analysis of Sharp Decline
Keywords: Q3 earnings double miss, increased net loss, going concern doubt
1. On November 9, ImmunityBio released its third quarter 2026 financial report. Adjusted net loss per share was $0.09, higher than analysts’ expected loss of $0.08; revenue was $48.841 million, below the expected $59.25 million, a shortfall of about 17.6%.
2. The GAAP diluted net loss per share for the third quarter was $0.18, significantly larger than $0.07 for the same period last year; net loss reached $184.6 million, compared to $67.3 million a year earlier.
3. Although revenue increased by 52.3% year-over-year, quarterly product sales fell quarter-over-quarter, and the growth was insufficient to meet the market’s high expectations for the commercial ramp-up of ANKTIVA.
4. In the earnings report, the company stated that it had “substantial doubt” about its ability to continue as a going concern in the absence of additional financing.
5. Over the past year, three directors collectively cashed out $9.51 million, and significant insider selling at a high level has drawn attention.
(Disclaimer: This content is collected from public information and summarized using AI technology. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Philippine Airlines will purchase 20 Boeing aircraft

Spot gold fell 2.62%, COMEX gold futures fell 4.19%